|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01276 HENGRUI PHARMA
Nominal 
58.000 +0.500 (+0.870%) Profitability Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| ROAA (%) | 13.493% | 9.988% | 9.219% |
| ROAE (%) | 14.739% | 10.991% | 10.328% |
| Return on Capital Employed (%) | 13.626% | 10.435% | 10.086% |
Margin Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| Gross Profit Margin (%) | 86.249% | 84.552% | 83.612% |
| EBITDA Margin (%) | 26.673% | 22.185% | 20.179% |
| Pre-tax Profit Margin (%) | 25.620% | 20.452% | 18.653% |
| Net Profit Margin (%) | 22.643% | 18.854% | 18.361% |
Liquidity Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| Current Ratio (X) | 9.719 X | 12.252 X | 8.500 X |
| Quick Ratio (X) | 9.054 X | 11.346 X | 7.827 X |
Leverage Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| Total Liabilities / Total Assets(%) | 8.069% | 6.284% | 9.341% |
| Total Debt / Total Assets (%) | 0.539% | 0.537% | 3.587% |
| Net Debt / Total Assets (%) | -48.932% | -46.845% | -32.075% |
| Total Debt / Shareholders' Funds (%) | 0.593% | 0.581% | 4.018% |
| Long Term Debt / Shareholders' Funds (%) | 0.152% | 0.186% | 0.261% |
| Net Debt / Shareholders' Funds (%) | -53.894% | -50.687% | -35.932% |
| Net Cash / (Debt) ($) | 24.532B | 20.511B | 13.591B |
| Net Cash / (Debt) per share ($) | -- | -- | -- |
| Total Debt / Capital Employed (%) | 0.581% | 0.570% | 3.924% |
| Interest Coverage Ratio (X) | 1290.745 X | 791.366 X | 612.384 X |
Efficiency Analysis
| 2024/12 | 2023/12 | 2022/12 | |
| Inventory Turnover (Day) | 224.375 Day | 246.661 Day | 256.539 Day |
| Receivables Turnover (Day) | 80.177 Day | 115.774 Day | 143.107 Day |
| Payables Turnover (Day) | 18.595 Day | 22.613 Day | 25.622 Day |
| Remarks: | Real time quote last updated: 30/05/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 6,336,527 |
| %Change | 47.278% |
| EPS / (LPS) | RMB 1.000 |
| NBV Per Share (¥) | RMB -- |